| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 2000;120:1078-1084
© 2000 The American Association for Thoracic Surgery
General Thoracic Surgery |
From the Division of General Thoracic Surgery,a University Hospital, Berne, Switzerland, the Institute of Biochemical Pharmacology,b University of Constance, Konstanz, Germany, and the Division of General Thoracic Surgery,c University Hospital, Zurich, Switzerland.
Supported by a grant from the EMDO-Stiftung.
Address for reprints: R. A. Schmid, MD, Division of Thoracic Surgery, University Hospital, 3010 Berne, Switzerland (E-mail: ralph.schmid{at}insel.ch).
Background: The nonspecific immune response with activation of the complement system and polymorphonuclear leukocytes is important for the mediation of reperfusion injury after lung transplantation. In this study, we investigated the combined blockade of the complement system and leukocyte adhesion by a novel drug combining soluble complement receptor type 1 (sCR1, CD35) with the selectin ligand sialyl Lewis X (sLeX, CD15s) synthesized to sCR1sLeX. Both sCR1 and sCR1sLeX were supplied by AVANT Immunotherapeutics, Inc, Needham, Massachusetts.
Methods: Orthotopic allogeneic single left lung transplantation was performed in male rats (Brown Norway to Fischer F344; n = 5 in all groups) after a total ischemic time of 20 hours. Recipients received either no specific treatment (control) or administration of sCR1 (10 mg/kg) or sCR1sLeX (10 mg/kg) 15 minutes before reperfusion by intracardiac injection. Twenty-four hours after reperfusion, the native contralateral lung was occluded to assess gas exchange of the graft only. In additional animals (5 per group), lung tissue was frozen 24 hours after reperfusion and assessed for myeloperoxidase activity as a measurement of neutrophil migration into the graft and thiobarbituric acid reactive substances to quantify lipid peroxidation.
Results: Graft function as assessed by arterial PO2 in recipients treated with sCR1sLeX was superior not only to that of controls (383 ± 53 vs 56 ± 7 mm Hg, P = .000095) but also to that of animals treated with sCR1 (243 ± 45 mm Hg, P = .031). This improvement was confirmed by significant reduction of neutrophil migration (0.33 ± 0.05 vs control, 1.0 ± 0.09 
OD/mg/min, P = .0000024) and lipid peroxidation (6.2 ± 0.38 vs control, 10.6 ± 0.54 pmol/g, P = .00021).
Conclusions: Our data indicate that combined inhibition of complement activation and leukocyte adhesion with sCR1sLeX reduces reperfusion injury significantly and that both mechanisms are effectively inhibited in this model.
This article has been cited by other articles:
|
|
 |
|
  C. Atkinson, H. Zhu, F. Qiao, J. C. Varela, J. Yu, H. Song, M. S. Kindy, and S. Tomlinson Complement-Dependent P-Selectin Expression and Injury following Ischemic Stroke J. Immunol., November 15, 2006; 177(10): 7266 - 7274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. He, M. Imai, H. Song, R. J. Quigg, and S. Tomlinson Complement Inhibitors Targeted to the Proximal Tubule Prevent Injury in Experimental Nephrotic Syndrome and Demonstrate a Key Role for C5b-9 J. Immunol., May 1, 2005; 174(9): 5750 - 5757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Keshavjee, R.D. Davis, M.R. Zamora, M. de Perrot, and G.A. Patterson A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings J. Thorac. Cardiovasc. Surg., February 1, 2005; 129(2): 423 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Thomas, K. Panneerselvam, D. T. Beattie, M. D. Picard, B. Xu, C. W. Rittershaus, H. C. Marsh Jr., R. A. Hammond, J. Qian, T. Stevenson, et al. Production of a complement inhibitor possessing sialyl Lewis X moieties by in vitro glycosylation technology Glycobiology, October 1, 2004; 14(10): 883 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.E. Dutly, I. Inci, S. Hillinger, M. Zalunardo, A. Gaspert, V. Rousson, B. Seifert, and W. Weder Normal gas exchange after 30-h ischemia and treatment with phosphodiesterase inhibitor PDI747 Eur. J. Cardiothorac. Surg., October 1, 2003; 24(4): 594 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. de Perrot, M. Liu, T. K. Waddell, and S. Keshavjee Ischemia-Reperfusion-induced Lung Injury Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 490 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. Riedemann and P. A. Ward Complement in Ischemia Reperfusion Injury Am. J. Pathol., February 1, 2003; 162(2): 363 - 367. [Full Text] [PDF]
|
|
|
|
|
|
U. Stammberger, J. Hamacher, J.-C. Pache, and R. A. Schmid sCR1sLeX reduces lung allograft ischemia-reperfusion injury but does not ameliorate acute rejection Eur. J. Cardiothorac. Surg., September 1, 2002; 22(3): 368 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. de Perrot and S. Keshavjee Lung preservation Ann. Thorac. Surg., August 1, 2002; 74(2): 629 - 631. [Full Text] [PDF]
|
|
|
|
|
|
D. Paparella, T.M. Yau, and E. Young Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 232 - 244. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
